Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance

Virology

Volumn 394, Issue 2, 2009, Pages 243-248

  Hightower, George K ^a   Letendre, Scott L ^a   Cherner, Mariana ^a   Gibson, Sarah A ^a   Ellis, Ronald J ^a,b   Wolfson, Tanya J ^a   Gamst, Anthony C ^a   Ignacio, Caroline C ^a   Heaton, Robert K ^a   Grant, Igor ^a,b   Richman, Douglas D ^a,b   Smith, Davey M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antiretroviral resistance; CSF viral load; Neuropathogenesis

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARAGINE; LYSINE; METHAMPHETAMINE; METHIONINE; VALINE; VIRUS RNA;

ADULT; ANAMNESIS; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG USE; FEMALE; GENERAL CONDITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HIV; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 70449089883     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.08.007     Document Type: Article

References (49)

1. Ances B.M., and Ellis R.J. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27 1 (2007) 86-92
2. Antinori A., Liuzzi G., Cingolani A., Bertoli A., Di Giambenedetto S., Trotta M.P., Rizzo M.G., Girardi E., De Luca A., and Perno C.F. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. Aids 15 17 (2001) 2325-2327
3. Antinori A., Giancola M.L., Grisetti S., Soldani F., Alba L., Liuzzi G., Amendola A., Capobianchi M., Tozzi V., and Perno C.F. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. Aids 16 14 (2002) 1867-1876
4. Antinori A., Perno C.F., Giancola M.L., Forbici F., Ippolito G., Hoetelmans R.M., and Piscitelli S.C. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41 12 (2005) 1787-1793
5. Antinori A., Arendt G., Becker J.T., Brew B.J., Byrd D.A., Cherner M., Clifford D.B., Cinque P., Epstein L.G., Goodkin K., Gisslen M., Grant I., Heaton R.K., Joseph J., Marder K., Marra C.M., McArthur J.C., Nunn M., Price R.W., Pulliam L., Robertson K.R., Sacktor N., Valcour V., and Wojna V.E. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69 18 (2007) 1789-1799
6. Barbour J.D., Wrin T., Grant R.M., Martin J.N., Segal M.R., Petropoulos C.J., and Deeks S.G. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76 21 (2002) 11104-11112
7. Brew B.J., Pemberton L., Cunningham P., and Law M.G. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J. Infect. Dis. 175 4 (1997) 963-966
8. Campbell T.B., Schneider K., Wrin T., Petropoulos C.J., and Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J. Virol. 77 22 (2003) 12105-12112
9. Cherner M., Letendre S., Heaton R.K., Durelle J., Marquie-Beck J., Gragg B., and Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64 8 (2005) 1343-1347
10. Clifford D.B., Yang Y., and Evans S. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J. Neurovirol. 11 Suppl. 3 (2005) 67-71
11. Collins J.A., Thompson M.G., Paintsil E., Ricketts M., Gedzior J., and Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 78 2 (2004) 603-611
12. Cong M.E., Heneine W., and Garcia-Lerma J.G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J. Virol. 81 6 (2007) 3037-3041
13. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., and Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344 7 (2001) 472-480
14. Deutsch R., Ellis R.J., McCutchan J.A., Marcotte T.D., Letendre S., and Grant I. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. Aids 15 14 (2001) 1898-1899
15. Ellis R.J., Hsia K., Spector S.A., Nelson J.A., Heaton R.K., Wallace M.R., Abramson I., Atkinson J.H., Grant I., and McCutchan J.A. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann. Neurol. 42 5 (1997) 679-688
16. Fischer-Smith T., Bell C., Croul S., Lewis M., and Rappaport J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J. Neurovirol. 14 4 (2008) 318-326
17. Giancola M.L., Lorenzini P., Balestra P., Larussa D., Baldini F., Corpolongo A., Narciso P., Bellagamba R., Tozzi V., and Antinori A. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 41 3 (2006) 332-337
18. Goudsmit J., De Ronde A., Ho D.D., and Perelson A.S. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70 8 (1996) 5662-5664
19. Harrigan P.R., Bloor S., and Larder B.A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72 5 (1998) 3773-3778
20. Heaton R.K., Cysique L.A., Jin H., Shi C., Yu X., Letendre S., Franklin Jr. D.R., Ake C., Vigil O., Atkinson J.H., Marcotte T.D., Grant I., and Wu Z. Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J. Neurovirol. (2008) 1-14
21. Iglesias-Ussel M.D., Casado C., Yuste E., Olivares I., and Lopez-Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. 83 Pt. 1 (2002) 93-101
22. Koelsch K.K., Smith D.M., Little S.J., Ignacio C.C., Macaranas T.R., Brown A.J., Petropoulos C.J., Richman D.D., and Wong J.K. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. Aids 17 7 (2003) F11-F16
23. Koval C.E., Dykes C., Wang J., and Demeter L.M. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology 353 1 (2006) 184-192
24. Letendre S.L., McCutchan J.A., Childers M.E., Woods S.P., Lazzaretto D., Heaton R.K., Grant I., and Ellis R.J. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 56 3 (2004) 416-423
25. Letendre S.L., Cherner M., Ellis R.J., Marquie-Beck J., Gragg B., Marcotte T., Heaton R.K., McCutchan J.A., and Grant I. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. Aids 19 Suppl. 3 (2005) S72-S78
26. Letendre S., Paulino A.D., Rockenstein E., Adame A., Crews L., Cherner M., Heaton R., Ellis R., Everall I.P., Grant I., and Masliah E. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J. Infect. Dis. 196 3 (2007) 361-370
27. Marra C.M., Zhao Y., Clifford D.B., Letendre S., Evans S., Henry K., Ellis R.J., Rodriguez B., Coombs R.W., Schifitto G., McArthur J.C., and Robertson K. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids 23 11 (2009) 1359-1366
28. Martinez-Picado J., and Martinez M.A. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134 1-2 (2008) 104-123
29. McArthur J.C. HIV dementia: an evolving disease. J. Neuroimmunol. 157 1-2 (2004) 3-10
30. McArthur J.C., McClernon D.R., Cronin M.F., Nance-Sproson T.E., Saah A.J., St Clair M., and Lanier E.R. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol. 42 5 (1997) 689-698
31. Nicastri E., Sarmati L., Dori L., Montano M., d'Ettorre G., Buonomini A.R., Parisi S.G., Concia E., Vullo V., and Andreoni M. Viral growth assay to evaluate the replicative capacity of HIV-1 isolates. J. Virol. Methods 115 2 (2004) 199-205
32. Paredes R., Sagar M., Marconi V.C., Hoh R., Martin J.N., Parkin N.T., Petropoulos C.J., Deeks S.G., and Kuritzkes D.R. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J. Virol. 83 4 (2009) 2038-2043
33. Perez-Bercoff D., Wurtzer S., Compain S., Benech H., and Clavel F. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J. Virol. 81 9 (2007) 4540-4550
34. Richardson J.L., Nowicki M., Danley K., Martin E.M., Cohen M.H., Gonzalez R., Vassileva J., and Levine A.M. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. Aids 19 15 (2005) 1659-1667
35. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., Wolfson T., and Grant I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 10 1 (2004) 1-14
36. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 8 Suppl. 2 (2002) 115-121
37. Samri A., Haas G., Duntze J., Bouley J.M., Calvez V., Katlama C., and Autran B. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74 19 (2000) 9306-9312
38. Schmitt M., Harrer E., Goldwich A., Bauerle M., Graedner I., Kalden J.R., and Harrer T. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. Aids 14 6 (2000) 653-658
39. Sevigny J.J., Albert S.M., McDermott M.P., McArthur J.C., Sacktor N., Conant K., Schifitto G., Selnes O.A., Stern Y., McClernon D.R., Palumbo D., Kieburtz K., Riggs G., Cohen B., Epstein L.G., and Marder K. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63 11 (2004) 2084-2090
40. Smith D.M., Wong J.K., Shao H., Hightower G.K., Mai S.H., Moreno J.M., Ignacio C.C., Frost S.D., Richman D.D., and Little S.J. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J. Infect. Dis. 196 3 (2007) 356-360
41. Spudich S., Lollo N., Liegler T., Deeks S.G., and Price R.W. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J. Infect. Dis. 194 12 (2006) 1686-1696
42. Spitzer, 1995 Spitzer. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders version IV 1995.
43. Tobin J. Estimation of relationships for limited dependent variables. Econometrica v26 (1958) 24-36
44. Tozzi V., Balestra P., Bellagamba R., Corpolongo A., Salvatori M.F., Visco-Comandini U., Vlassi C., Giulianelli M., Galgani S., Antinori A., and Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune Defic. Syndr. 45 2 (2007) 174-182
45. Vitiello B., Goodkin K., Ashtana D., Shapshak P., Atkinson J.H., Heseltine P.N., Eaton E., Heaton R., and Lyman W.D. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. Aids 21 11 (2007) 1415-1422
46. Wang J., Dykes C., Domaoal R.A., Koval C.E., Bambara R.A., and Demeter L.M. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 348 2 (2006) 462-474
47. Weber J., Chakraborty B., Weberova J., Miller M.D., and Quinones-Mateu M.E. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol. 43 3 (2005) 1395-1400
48. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., and Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46 11 (2002) 3437-3446
49. Woods S.P., Rippeth J.D., Frol A.B., Levy J.K., Ryan E., Soukup V.M., Hinkin C.H., Lazzaretto D., Cherner M., Marcotte T.D., Gelman B.B., Morgello S., Singer E.J., Grant I., and Heaton R.K. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J. Clin. Exp. Neuropsychol. 26 6 (2004) 759-778